13.10
+1.24%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Chongqing Pharscin Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 002907.SZ. It has been listed since 20 October 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥827.1m and net income of CN¥65.1m. At that date it held total assets of CN¥2.03bn and shareholders' equity of CN¥1.69bn.
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical and Chinese medicine. The company is headquartered in Chongqing, Chongqing. The company went IPO on 2017-10-20. The firm operates three segments: Pharmaceutical Industry segment, Commercial Circulation segment and Retail segment. The firm's products are categorized into the pharmaceuticals of digestive system, nervous system, otorhinolaryngology, cardiovascular and cerebrovascular systems and immune systems. The Company’s products include Weidimei (aluminum carbonate tablets), Ganju Bingmei Tablets, Bawei Qilong Particles, Liuwei Anshen Capsules, Sodium Ferulate for Injection, Omeprazole Sodium for Injection and Gabexate Mesilate for Injection. The firm mainly distributes its products in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Oct 2017
- Employees
- 1,416
- Website
- pharscin.com ↗
Leadership
Pay as last reported
- Mr. Hongtao YouChairman of the Board, General Manager, since 2015CN¥411,200
- Ms. Xiaoyan PengChief Financial OfficerCN¥232,700
- Ms. Xuedan YouDeputy General Manager, Secretary of the Board, Director, since 2015CN¥253,900
- Ms. Yuanyi YouDeputy General Manager, Director, since 2019CN¥12,500
- Mr. Jie HuangDeputy General Manager
- Ms. Ying WangDeputy General Manager, since 2015CN¥404,600
- Ms. Yan LiangDirector
- Mr. Hao ShenDirector
- Mr. Kaiyu XuStaff Elected Director
- Ms. Shouying DuIndependent DirectorCN¥26,600
- Mr. Jiaming LiIndependent Director
- Ms. Shaorong QinIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Chongqing Pharscin employs 1,416 skilled workers in Chongqing for pharmaceutical production.
- The company's three segments cover Pharmaceutical Industry, Commercial Circulation, and Retail operations.
- Chongqing Pharscin offers diverse products like Weidimei and Ganju Bingmei Tablets for digestive and nervous systems.
Weaknesses
- The firm's domestic market focus limits international expansion opportunities.
- Chongqing Pharscin's products are limited to digestive and nervous system treatments.
- The company's IPO in 2017 may indicate limited recent capital growth.
Opportunities
- Expanding into cardiovascular and cerebrovascular systems could increase market share.
- Chongqing Pharscin could leverage its retail segment for broader domestic distribution.
- Growing demand for Chinese medicine presents a significant opportunity.
Threats
- Competition from other domestic pharmaceutical firms in China is intense.
- Regulatory changes in the Chinese Health Care sector could impact operations.
- The company's reliance on domestic market makes it vulnerable to local economic shifts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.